Soleil Boughton Sells 4,152 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the transaction, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70.

Hims & Hers Health Price Performance

HIMS opened at $49.10 on Friday. The stock has a 50-day moving average price of $35.05 and a 200-day moving average price of $25.70. The firm has a market cap of $10.73 billion, a PE ratio of 111.58 and a beta of 1.35. Hims & Hers Health, Inc. has a 1 year low of $9.25 and a 1 year high of $72.98.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of the stock. SlateStone Wealth LLC raised its position in Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. raised its position in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares during the last quarter. Summit Investment Advisors Inc. raised its position in Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after buying an additional 628 shares during the last quarter. Quest Partners LLC raised its position in Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares during the last quarter. Finally, Harbour Investments Inc. raised its position in Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after buying an additional 833 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of several recent analyst reports. TD Cowen reiterated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price target for the company from $24.00 to $25.00 in a report on Friday, January 10th. Piper Sandler lifted their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $42.00 to $60.00 in a report on Tuesday. Finally, BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.